UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

European heart journal, 2021-01, Vol.42 (2), p.152-161

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

The New England journal of medicine, 2020-12, Vol.383 (23), p.2219-2229

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease

British journal of pharmacology, 2022-07, Vol.179 (13), p.3220-3234

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular mechanisms and therapeutic targets for diabetic kidney disease

Kidney international, 2022-08, Vol.102 (2), p.248-260

2022

Link zum Volltext

Verfügbarkeit prüfen

Nonsteroidal antagonists of the mineralocorticoid receptor

Current opinion in nephrology and hypertension, 2015-09, Vol.24 (5), p.417-424

2015

Link zum Volltext

Verfügbarkeit prüfen

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity

Hypertension (Dallas, Tex. 1979), 2018-04, Vol.71 (4), p.599-608

2018

Link zum Volltext

Verfügbarkeit prüfen

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling

Biochemical pharmacology, 2019-10, Vol.168, p.173-183

2019

Link zum Volltext

Verfügbarkeit prüfen

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

Kidney international, 2018-06, Vol.93 (6), p.1344-1355

2018

Link zum Volltext

Verfügbarkeit prüfen

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

American journal of nephrology, 2019, Vol.50 (5), p.333-344

2019

Link zum Volltext

Verfügbarkeit prüfen

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems

International journal of molecular sciences, 2022-08, Vol.23 (16), p.9243

2022

Link zum Volltext

Verfügbarkeit prüfen

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside

Handbook of experimental pharmacology, 2017-01, Vol.243, p.271-305

2017

Link zum Volltext

Verfügbarkeit prüfen

Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

Expert opinion on investigational drugs, 2021-11, Vol.30 (11), p.1141-1157

2021

Link zum Volltext

Verfügbarkeit prüfen

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro

Drug metabolism and disposition, 2018-11, Vol.46 (11), p.1546-1555

2018

Link zum Volltext

Verfügbarkeit prüfen

Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis

American journal of nephrology, 2021-09, Vol.52 (7), p.588-601

2021

Link zum Volltext

Verfügbarkeit prüfen

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

Journal of endocrinology, 2017-07, Vol.234 (1), p.T125-T140

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Journal of hypertension, 2023-02, Vol.41 (2), p.295

2023

Link zum Volltext

Verfügbarkeit prüfen

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

The Journal of biological chemistry, 2015-09, Vol.290 (36), p.21876-21889

2015

Link zum Volltext

Verfügbarkeit prüfen

Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells

The FASEB journal, 2021-02, Vol.35 (2), p.e21314-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

Journal of cardiovascular pharmacology, 2014-07, Vol.64 (1), p.69-78

2014

Link zum Volltext

Verfügbarkeit prüfen

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1

Journal of the American Society of Nephrology, 2017-04, Vol.28 (4), p.1216-1226

2017

Link zum Volltext

Verfügbarkeit prüfen

Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction

Hypertension (Dallas, Tex. 1979), 2016-04, Vol.67 (4), p.717-723

2016

Link zum Volltext

Verfügbarkeit prüfen

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2334

2023

Link zum Volltext

Verfügbarkeit prüfen

A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule

The Journal of biological chemistry, 2010-09, Vol.285 (39), p.29932-29940

2010

Link zum Volltext

Verfügbarkeit prüfen

Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice

Journal of molecular and cellular cardiology, 2018-08, Vol.121, p.124-133

2018

Link zum Volltext

Verfügbarkeit prüfen

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury

PloS one, 2017-09, Vol.12 (9), p.e0184888

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(111)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(82)
Humans
(45)
Animals
(38)
Male
(34)
Cardiovascular System & Cardiology
(30)
Heart Failure
(26)
Finerenone
(24)
Kidney Diseases
(22)
Cardiac & Cardiovascular Systems
(21)
Chronic Kidney Disease
(21)
Diabetes
(19)
Female
(19)
Mineralocorticoid Receptor Antagonists - Therapeutic Use
(19)
Pharmacology & Pharmacy
(19)
Mineralocorticoid Receptor Antagonists - Pharmacology
(18)
Naphthyridines - Pharmacology
(17)
Aldosterone
(16)
Diabetes Mellitus, Type 2 - Complications
(16)
Naphthyridines - Therapeutic Use
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease

Molecular mechanisms and therapeutic targets for diabetic kidney disease

Nonsteroidal antagonists of the mineralocorticoid receptor

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside

Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro

Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1

Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy

A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule

Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury

Suchergebnisse filtern